The Nose Knows: Nose to Brain Targeting Mechanism and Recent Advances


, , ,

By Rakesh Gollen

Rakesh GollenBiologics represents a new category of drugs that have rapidly gained momentum in the past decade, as drugs of biological origin are increasing in the pharmaceutical arena. Peptides and proteins have become the drugs of choice for the treatment of numerous diseases due to their incredible selectivity and their ability to provide effective and potent action. In general, they cause few side effects, are highly specific, present limited interferences with normal biological processes, have low immunogenicity, and have great potential to cure diseases rather than merely to treat the symptoms. Apart from these benefits, from a business point of view, they hasten clinical development, and thus approval time, and they enjoy greater patent protection. Continue reading

AAPS Pharmaceutical Science Roundup, August 2014


, , , , , , , , , , , , , ,

May2014NewsThis month’s roundup features experimental Ebola drugs, a new cold sore treatment, developments in ALS research, and much more!

Have a perspective on one of these stories? Submit your post to the AAPS Blog! Continue reading

Herd Immunity: Why Is It So Important?


, , ,

This post has been adapted from a post written for the Colorado Children’s Immunization Coalition’s Team Vaccine Blog and the Immunology 101 Series.

By Aimee Pugh-Bernard

Aimee Pugh-Bernard2As a scientist, and an educator, and a mother of ten-year-old twins, I’m attentive to kids’ health. Over the past year, there have been a record number of cases of whooping cough (pertussis) and measles across the country. As a scientist and educator, this news presents a challenge. As a parent, it is worrisome. The choices we make as parents regarding immunizing our children affect not only our children, but those around them, also known as “herd immunity.” Continue reading

AAPS Immunogenicity Week: Immunotherapy for Cancer


, , , , , , ,

By David Warmflash

David WarmflashImmunotherapy for cancer is based on the idea that the immune system can be modulated to improve tumor-specific responses and to interfere with tumor tolerance. Immune activity against malignant tissue depends on the activation of innate immune cells, as well as natural killer (NK) cells, macrophages, neutrophils, mastocytes, and dentritic cells (DCs). Found in nearly every kind of body tissue, DCs capture antigens, including those on tumor cells, and carry them to secondary lymphoid organs. There, they activate naïve T cells. Control of the various immune cells depends on agents known as cytokines and chemokines, and on immune cells known as B and T lymphocytes. Continue reading

AAPS Immunogenicity Week: Expanding Access to Immunogenicity Training for an Expanding Biotech Industry


, , ,

Adrienne Clements EganBy Adrienne Clements-Egan, Ph.D.

Within the top 100 selling drug products, the percentage of sales generated by biotherapeutics has increased from 17% in 2004 to 39% in 2012. Furthermore, it is predicted that by 2018, around 50% of sales (within the top 100 products) will be generated by biotherapeutics. With this expansion in the biotech industry and the dawn of opportunities in biosimilars, it has become important to expand access to education on the key topics related to biotherapeutic drug development. In 2011, as part of an effort to serve its members and the greater global pharmaceutical field, AAPS produced the eCourse Biotechnology 101: Fundamentals of Biotherapeutics Development eLearning Series, which provided the convenience of online learning without the need to travel to biotechnology conferences for the information. Continue reading


Get every new post delivered to your Inbox.

Join 164 other followers